Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Tyme Technologies Inc (TYME) USD0.0001

Sell:$0.86 Buy:$0.89 Change: $0.0459 (5.02%)
NASDAQ:2.45%
Market closed |  Prices as at close on 30 October 2020 | Switch to live prices |
Sell:$0.86
Buy:$0.89
Change: $0.0459 (5.02%)
Market closed |  Prices as at close on 30 October 2020 | Switch to live prices |
Sell:$0.86
Buy:$0.89
Change: $0.0459 (5.02%)
Market closed |  Prices as at close on 30 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

TYME Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. The Company’s lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. SM-88 is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. The Company has multiple cancer metabolism-based assets and other formulations for SM-88 in the pipeline, including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting.

Contact details

Address:
1 PLUCKEMIN WAY - SUITE 103
BEDMINSTER
07921
United States
Telephone:
+1 (212) 4612315
Website:
https://www.tymeinc.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TYME
ISIN:
US90238J1034
Market cap:
$115.97 million
Shares in issue:
126.88 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Steve Hoffman
    Chairman of the Board, Chief Executive Officer, Chief Science Officer
  • Barbara Galaini
    Principal Financial Officer, Principal Accounting Officer, Corporate Controller
  • Michele Korfin
    Chief Operating Officer
  • Giuseppe Del Priore
    Chief Medical Officer
  • Jonathan Eckard
    Chief Business Officer
  • James Biehl
    Chief Legal Officer and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.